Literature DB >> 15158611

Cross-linking of CD40 using anti-CD40 antibody, 5C11, has different effects on XG2 multiple myeloma cells.

Chun-Jian Qi1, Lu Zheng, Xuan Zhou, Yi Tao, Yan Ge, Yu-Mei Zhuang, Yin Xu, GeHua Yu, Xue-Guang Zhang.   

Abstract

A multiple myeloma (MM) cell line, XG2, has high-level expression of CD40, a tumor necrosis factor receptor (TNFR) family member. CD40 is present on the surfaces of a large variety of cells, including B cells, endothelial cells, dendritic cells and some carcinoma cells, and delivers signals regulating diverse cellular responses, such as proliferation, differentiation, growth suppression, cell death. In this research, we study the effects of cross-linking of CD40 on myeloma cells using different concentrations of anti-CD40 monoclonal antibody (mAb), 5C11. We found that low concentrations of 5C11 induced proliferation of XG2, while high concentrations of 5C11 resulted in homotypic aggregation of XG2, and strongly suppression of its proliferation and apoptosis after 24 h of treatment. These dose-dependent effects of 5C11 were verified by flow cytometry, Western blotting and immunoprecipitation. Autocrine or paracrine induction of IL-6, and up-regulation of membrane TNF and phosphorylation of TNFR1 may partially explain the contradictory biological effects of CD40 cross-linking on XG2 by anti-CD40 mAb.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158611     DOI: 10.1016/j.imlet.2004.03.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction.

Authors:  Sonia Néron; Claudia Racine; Annie Roy; Matthieu Guérin
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

2.  Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.

Authors:  Jing Yang; Yabing Cao; Sungyongl Hong; Haiyan Li; Jianfei Qian; Larry W Kwak; Qing Yi
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.